Associations - Osteosarcoma

No biomarker No biomarker	Osteosarcoma Osteosarcoma	doxorubicin hydrochloride Sensitive: A1 - Approval
No biomarker No biomarker	Osteosarcoma Osteosarcoma	ADX-2191 Sensitive: A1 - Approval
No biomarker No biomarker	Osteosarcoma Osteosarcoma	regorafenib Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	IE Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	gemcitabine + docetaxel + cyclophosphamide oral Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	cyclophosphamide oral + regorafenib Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	sorafenib + cyclophosphamide oral Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	carboplatin + cyclophosphamide oral + etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	carboplatin + cyclophosphamide oral Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	cyclophosphamide oral + etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	gemcitabine + docetaxel + ifosfamide Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	carboplatin + ifosfamide + etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	carboplatin + ifosfamide Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	cisplatin + ifosfamide + methotrexate + SGN-15 Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	cisplatin + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	ifosfamide + etoposide oral + methotrexate Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	sorafenib + everolimus Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	gemcitabine + docetaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	cyclophosphamide oral + topotecan Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	cabozantinib tablet Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	sorafenib Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	ifosfamide Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	cisplatin + SGN-15 + methotrexate IV Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	cisplatin + SGN-15 Sensitive: A2 - Guideline
TMB-H TMB-H	Osteosarcoma Osteosarcoma	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Osteosarcoma Osteosarcoma	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	MAP Sensitive: A2 - Guideline
No biomarker No biomarker	Osteosarcoma Osteosarcoma	methotrexate Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Osteosarcoma Osteosarcoma	larotrectinib Sensitive: C1 - Off-label
NTRK1 fusion NTRK1 fusion	Osteosarcoma Osteosarcoma	larotrectinib Sensitive: C1 - Off-label
NTRK3 fusion NTRK3 fusion	Osteosarcoma Osteosarcoma	larotrectinib Sensitive: C1 - Off-label
ERCC1 K504Q ERCC1 K504Q	Osteosarcoma Osteosarcoma	cisplatin Resistant: C3 – Early Trials
XPC K939G XPC K939G	Osteosarcoma Osteosarcoma	cisplatin Sensitive: C3 – Early Trials
ERCC2 K751G ERCC2 K751G	Osteosarcoma Osteosarcoma	cisplatin Resistant: C3 – Early Trials
ERCC1 N118N ERCC1 N118N	Osteosarcoma Osteosarcoma	cisplatin Resistant: C3 – Early Trials
ERCC2 D312N ERCC2 D312N	Osteosarcoma Osteosarcoma	cisplatin Resistant: C3 – Early Trials
ABCG2 overexpression ABCG2 overexpression	Osteosarcoma Osteosarcoma	MAP Resistant: C3 – Early Trials
PGP overexpression PGP overexpression	Osteosarcoma Osteosarcoma	ifosfamide + mifamurtide Sensitive: C3 – Early Trials
TAF15-CHN1 translocation TAF15-CHN1 translocation	Osteosarcoma Osteosarcoma	SP2577 Sensitive: C3 – Early Trials
EGFR overexpression EGFR overexpression	Osteosarcoma Osteosarcoma	gemcitabine Resistant: D – Preclinical
IGF1R expression IGF1R expression	Osteosarcoma Osteosarcoma	IGF-1R inhibitor Sensitive: D – Preclinical
RB1 positive RB1 positive	Osteosarcoma Osteosarcoma	palbociclib Sensitive: D – Preclinical

Osteosarcoma

Associations(43)

Associations
(43)